Investment in Genomics, Advanced Therapies, and Precision Health Accelerate the Growth of the UK MedTech Sector
Innovation culture in the life sciences sector enables growth despite the short-term impact of COVID-19 and Brexit
Click image to view it in full size
Traditional Medtech market revenues are expected to slow down by 2024. How are you planning to boost growth in the UK Medtech market, especially in the wake of Brexit, Covid 19 and other regional market challenges?
With this research study, Frost & Sullivan is analyzing the total landscape of the UK MedTech sector, including market trends, drivers, and restraints, and performs market forecast assessment. The study examines the historical data on revenue turnover from Office of Life Sciences, and performs a forecast by considering several factors including Brexit, Covid 19, milestones earmarked in the UK Life Sciences Sector Deal, Life Sciences Recovery Roadmap and other relevant strategic initiatives.
Frost & Sullivan has identified 5 growth opportunities in the light of recent market developments and by evaluating the investments outlined by Life Sciences sector deal. It also covers the growth environment with specific focus on clusters of growth within the UK MedTech sector.
Take your first step towards achieving growth-centric solutions with our
Growth Pipeline Dialog™. Speak to our industry experts in a complimentary open discussion that will spark innovative thinking and growth opportunities that will benefit your organization.
